• Pfizer presented Phase 3 results showing LITFULO improved facial repigmentation and overall skin repigmentation in nonsegmental vitiligo versus placebo.
• Benefits built over time, with continued improvement from mid-study through one year, supporting a systemic treatment approach for the disease.
• Safety matched the drug’s established profile in alopecia areata, with no new safety signals reported in the vitiligo program.
• Pfizer plans regulatory submissions to the FDA and EMA, aiming to expand LITFULO beyond its current alopecia areata indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610021115BIZWIRE_USPR_____20261002_BW026421) on October 02, 2026, and is solely responsible for the information contained therein.